Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Medarex on $2.4B Merger with Bristol-Myers Squibb


NEW YORK, NY, July 22, 2009 — Medarex and Bristol-Myers Squibb announced today that Bristol-Myers Squibb entered into an agreement for Bristol-Myers Squibb to acquire all of the outstanding stock and stock equivalents of Medarex for $16.00 in cash per share, or aggregate consideration of $2.4 billion. Covington & Burling LLP advised Medarex on the transaction.

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life.

The New York and Washington based Covington team was led by corporate partners Scott Smith, John Hurvitz and Stephen Infante, with associates Donald Saelinger, Russell Valdez and Richard Kruger. Also advising on the transaction were partner Robert Newman and associate Austen Townsend (benefits), partner Corinne Goldstein (environmental), partner Scott Danzis and associate Laura Sim (food & drug), and partners Tom Barnett and James Dean (antitrust). In addition, partner Rob Heller advised on tax aspects, and partner Lee Tiedrich provided IP advice, along with associate Jessica Milner.

Share this article: